Research progress of CAR-T in the treatment of hepatocellular carcinoma / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
;
(12): 146-150, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-932749
ABSTRACT
In recent years, chimeric antigen receptor-modified T-cell (CAR-T) immunotherapy, as a new idea of tumor immunotherapy, has been proved to be effective in hematological diseases. More and more studies have been focusing on this field. At present, some progress have been made in the treatment of hepatocellular carcinoma with CAR-T, but some problems such as solid tumor inherent barrier, tumor microenvironment, immune escape and specific tumor associated antigens still need to be further figure out. Nevertheless, CAR-T immunotherapy will provide a more cutting-edge treatment for hepatocellular carcinoma immunotherapy. In addition, the combination of CAR-T and other methods may also be the direction to be explored in the next step.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Hepatobiliary Surgery
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS